Combined perifosine (PI3K/AKT inhibitor) and radiotherapy for prostate cancer

被引：0
|
作者：
Gao, Y. [1 ,2 ,3 ]
Wang, X. [1 ,4 ,5 ]
Zhu, J. [1 ]
Mai, W. [1 ]
Huang, Y. [1 ,2 ,3 ]
Floryk, D.
Ittmann, M.
Butler, E. B.
Teh, B. S. [1 ]
机构：
[1] Baylor Coll Med, Methodist Hosp, Michael E DeBakey VA Med Center, Houston, TX 77030 USA
[2] Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol So China, Guangzhou 510275, Guangdong, Peoples R China
[3] Sun Yat Sen Univ, Ctr Canc, Dept Expt Res, Guangzhou 510275, Guangdong, Peoples R China
[4] Peking Union Med Coll, Beijing 100021, Peoples R China
[5] Chinese Acad Med Sci, Canc Hosp, Beijing 100037, Peoples R China
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2008年 / 72卷 / 01期
关键词：
D O I：
10.1016/j.ijrobp.2008.06.546
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S712 / S713
页数：2
相关论文
共 50 条
  • [1] Perifosine (PI3K/AKT Inhibitor) Enhanced Radiation Anti-tumor Efficacy in Prostate Cancer: What is the Optimum Sequence and Timing of the Combined Approach?
    Ishiyama, H.
    Sun, M.
    Gao, Y.
    Danforth, R.
    Wang, H.
    Chunying, Y.
    Brinkman, K.
    Butler, E. B.
    Xu, B.
    The, B. S.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 78 (03): : S658 - S659
  • [2] Exploration of biologic significances and mechanisms of combined atorvastatin with PI3K/Akt inhibitor in radiotherapy of colorectal cancer
    Cheng, C. H.
    [J]. ANNALS OF ONCOLOGY, 2019, 30
  • [3] The PI3K/AKT pathway in the pathogenesis of prostate cancer
    Chen, Huixing
    Zhou, Lan
    Wu, Xiaorong
    Li, Rongbing
    Wen, Jiling
    Sha, Jianjun
    Wen, Xiaofei
    [J]. FRONTIERS IN BIOSCIENCE-LANDMARK, 2016, 21 : 1084 - 1091
  • [4] Targeting PI3K/Akt signaling in prostate cancer therapy
    Hashemi, Mehrdad
    Taheriazam, Afshin
    Daneii, Pouria
    Hassanpour, Aria
    Kakavand, Amirabbas
    Rezaei, Shamin
    Hejazi, Elahe Sadat
    Aboutalebi, Maryam
    Gholamrezaie, Hamidreza
    Saebfar, Hamidreza
    Salimimoghadam, Shokooh
    Mirzaei, Sepideh
    Entezari, Maliheh
    Samarghandian, Saeed
    [J]. JOURNAL OF CELL COMMUNICATION AND SIGNALING, 2023, 17 (03) : 423 - 443
  • [5] Targeting the PI3K/AKT Pathway for the Treatment of Prostate Cancer
    Sarker, Debashis
    Reid, Alison H. M.
    Yap, Timothy A.
    de Bono, Johann S.
    [J]. CLINICAL CANCER RESEARCH, 2009, 15 (15) : 4799 - 4805
  • [6] Targeting PI3K/Akt signaling in prostate cancer therapy
    Mehrdad Hashemi
    Afshin Taheriazam
    Pouria Daneii
    Aria Hassanpour
    Amirabbas kakavand
    Shamin Rezaei
    Elahe Sadat Hejazi
    Maryam Aboutalebi
    Hamidreza Gholamrezaie
    Hamidreza Saebfar
    Shokooh Salimimoghadam
    Sepideh Mirzaei
    Maliheh Entezari
    Saeed Samarghandian
    [J]. Journal of Cell Communication and Signaling, 2023, 17 : 423 - 443
  • [7] PI3K/AKT DUAL INHIBITOR RESTORES DOCETAXEL SENSITIVITY IN CASTRATION RESISTANT PROSTATE CANCER
    Yasumizu, Yota
    Miyajima, Akira
    Kosaka, Takeo
    Shirotake, Suguru
    Kikuchi, Eiji
    Oya, Mototsugu
    [J]. JOURNAL OF UROLOGY, 2012, 187 (04): : E394 - E395
  • [8] Radiosensitisation properties of PI3K/AKT inhibitor GDC-0941 in prostate cancer cells
    Floyd, R.
    McDermott, N.
    Meunier, A.
    Marignol, L.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2015, 115 : S572 - S572
  • [9] PI3K/Akt signalling regulates leucine transport in prostate cancer
    Zhang, Kun
    Moran, Anne
    Holst, Jeff
    Wang, Qian
    [J]. BJU INTERNATIONAL, 2015, 116 : 34 - 35
  • [10] The impact of PI3K/AKT inhibitor on the radiosensitization of breast cancer cells
    Fu, S
    Zeng, QW
    Sun, Y
    Zhang, Q
    Shao, YH
    Jian, GL
    [J]. RADIOTHERAPY AND ONCOLOGY, 2006, 78 : S93 - S93
12345